Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why
1. VIR biotech presents initial Phase 1 data for T-cell engagers. 2. Early data shows 50% tumor shrinkage in HER2-positive tumors. 3. Morgan Stanley upgrades VIR from Equal-weight to Overweight with $20 target. 4. Encouraging results indicate potential revenue from prostate cancer treatment.